Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus' arguments in a patent infringement lawsuit related to Moderna's blockbuster COVID-19 vaccines.

Moderna shares fall after judge sides with Arbutus in patent fight

Moderna had a challenging 2023 as demand for its COVID-19 vaccines declined, but it still expects reasonable revenue in 2024. The company has a strong pipeline of products, including respiratory vaccines and potential joint flu/COVID-19 vaccines. Moderna's financial picture remains volatile, but it has a strong cash position and is investing heavily in R&D to build new businesses.

Moderna Continues To Build A Pipeline

CAMBRIDGE, MA / ACCESSWIRE / April 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that interim data for a first-in-human, phase 1/2, open-label, dose optimization study and extension study, evaluating the safety and efficacy of mRNA-3927, an investigational mRNA therapy for propionic acidemia (PA), has been published in Nature. "We are excited to share the first published clinical data utilizing an mRNA therapy for intracellular protein replacement," said Kyle Holen, M.D.

Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature

The analyst is so convinced of future success that he set a price target more than 100% above the current level. He cited likely U.S. regulatory approval for an RSV vaccine as only one factor in this.

Is Moderna Stock Going to $214? 1 Wall Street Analyst Thinks So.

Pfizer

Vaccine makers Pfizer and Moderna lost much of their steam as the pandemic started receding. However, both businesses are making significant strides and their shares should bounce back.

2 Stocks Down 30% and 27% to Buy and Hold

Moderna has proven that its approach can work, making an investment less risky. In addition to its COVID-19 vaccine, the company is developing other products.

Moderna Stock: Buy, Sell, or Hold?

Pfizer and Moderna, both coronavirus vaccine stars, now face declining demand -- and, as a result, declining revenue. But these top companies are expanding their growth potential with new candidates targeting various treatment areas.

Better Recovery Story Buy: Pfizer vs Moderna

Moderna (MRNA) posts data on three experimental vaccines and intends to advance them to late-stage studies. It also secures $750 million in funding from Blackstone to advance its influenza program.

Moderna (MRNA) Posts Pipeline Progress, Secures Blackstone Funding

Neurocrine Biosciences

Vertex Pharmaceuticals

“Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024.

Three top U.S. biotech stocks to buy in April

CRISPR Therapeutics

Bio-Techne

Last year was a tough one for biotech stocks. The Securities and Exchange Commission reported 41 bankruptcies following the Fed's interest rate hiking cycle, making it difficult to finance debt.

3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition

Intellia Therapeutics

Cathie Wood added to her positions in these biotech stocks this week. The famous investor seeks out undervalued innovators to add to her funds and hold onto for the long term.

Better Cathie Wood Stock: Moderna vs. Intellia

Moderna Inc   (NASDAQ:MRNA) is 1.8% higher to trade at $109.29 at last check, after the company received $750 million in funding from Blackstone Life Sciences (BX) to develop mRNA flu vaccines.

Moderna Stock Pops After Acquiring Millions in Funding

Moderna Inc. (MRNA) shares advanced Wednesday as the biotech firm used its “Vaccines Day” event to make key announcements about new funding and the results of several vaccine trials.

Moderna Gets $750 Million in Flu Shot Funding, Stock Advances

Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.

Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study

Moderna Inc. saw its stock continue its downward trajectory on Wednesday morning, slipping by 1.2 percent to $106.21, following a decline of over 3 percent on Tuesday. The biotech company's shares have endured a 28% drop over the past year.

Moderna shares continue to fall even as its 3 vaccines enter final stage trials

SHANGHAI , March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Annual Results. Business Highlights Zevorcabtagene autoleucel (CT053) NDA was approved by the NMPA.

CARsgen Announced 2023 Annual Results

Moderna will chart its post-Covid future Wednesday during its fifth annual "Vaccines Day," an investor event in Boston.

Moderna moves three vaccines into final stage trials as it works to rebound from Covid slump

The vaccine maker announces that Blackstone Life Sciences has agreed to fund up to $750 million for its flu program.

Moderna Gets $750 Million for Flu Program. Funding to Help Move Beyond Covid Vaccines.

Blackstone Group

Moderna said on Wednesday it has entered into an agreement with private equity firm Blackstone's life science investment platform for a funding of $750 million to develop its mRNA flu vaccines.

Moderna gets $750 mln funding from Blackstone Life Sciences to develop flu shots

NEW YORK--(BUSINESS WIRE)--Blackstone (NYSE:BX) announced today a new collaboration with Moderna, Inc. (NASDAQ: MRNA, “Moderna”) through a development and commercialization funding agreement where funds managed by Blackstone Life Sciences (“Blackstone”) will provide up to $750 million to fund Moderna's influenza (“flu”) program. “Moderna has demonstrated a remarkable ability to impact human health through mRNA vaccines targeting respiratory illnesses. This landmark collaboration is another exam.

Blackstone Life Sciences Announces Collaboration to Support Moderna's Influenza Program

Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpoints Expects two more Phase 3 readouts in 2024, including combination vaccine against flu and COVID-19, and vaccine against CMV Announces positive clinical trial data from three new vaccines against viruses that cause significant burden (Epstein-Barr virus, Varicella-Zoster virus, norovirus) and advances programs toward Phase 3 development Anticipates U.S. launch of vaccine against RSV following FDA approval and ACIP recommendation in 2024 Announces development and commercialization funding agreement with Blackstone Life Sciences for up to $750 million to advance flu program CAMBRIDGE, MA / ACCESSWIRE / March 27, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced at its fifth Vaccines Day event clinical and program updates demonstrating advancement and acceleration of its mRNA pipeline. The updates include data readouts in the Company's respiratory and latent and other vaccine portfolios, as well as commercial, manufacturing and financial announcements for its vaccines business.

Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna Inc. (MRNA) on Tuesday reported "positive interim results" from a late-stage study of what it calls the "next-generation COVID-19 vaccine."

Moderna Says 'Next-Generation' COVID-19 Shot Had Positive Phase 3 Test Results

Moderna's new shot offers the potential of a longer shelf life and is one component of its combination vaccine targeting Covid and the flu.

Moderna says new Covid vaccine showed stronger immune response than current shot in study

Moderna's ‘next generation,' Covid-19 vaccine has shown a higher immune response to the virus than the current version of the shot.

Moderna Stock Pops as New Covid-19 Vaccine Shows Positive Results

Shares of Moderna Inc. MRNA, +4.70% rose 1.1% in premarket trading Tuesday, after the biotechnology company said its next-generation COVID-19 vaccine produced positive results in a late-stage trial. The company said mRNA-1283 has met the primary endpoints of a Phase 3 trial, as it demonstrated a higher immune response against the Omicron BA.4/BA.5 virus strains of COVID-19.

News for Moderna Stock (MRNA)